After a delay in their original filing plans, uniQure N.V. and CSL Limited (CSL Behring) have come back with Phase III data on etranacogene dezaparvovec (EtranaDez) in hemophilia B that should be sufficient to seek US Food and Drug Administration approval for the gene therapy in the first half of 2022, in addition to opening up a significant commercial opportunity.
The companies said on 9 December that the HOPE-B trial met the primary endpoint of non-inferiority in annualized bleeding rate...








